PROCEPT BioRobotics Corporation - Common Stock (PRCT)
22.69
-5.15 (-18.50%)
NASDAQ · Last Trade: Feb 26th, 1:44 PM EST
There are notable gap-ups and gap-downs in today's session.chartmill.com
Via Chartmill · February 26, 2026
Get insights into the top gainers and losers of Thursday's pre-market session.chartmill.com
Via Chartmill · February 26, 2026

PROCEPT BioRobotics (NASDAQ: PRCT) shares down on Q4 2025 results and updated revenue guidance. Q1 sales expected at $79-82 million.
Via Benzinga · February 26, 2026
Bank of America reduced its rating on PROCEPT BioRobotics to ‘Underperform’ from ‘Neutral’.
Via Stocktwits · February 26, 2026
PROCEPT BioRobotics Corp (NASDAQ:PRCT) Plummets 27% After Q4 Earnings Miss and Slashed 2026 Guidancechartmill.com
Via Chartmill · February 25, 2026
Top movers in Wednesday's after hours sessionchartmill.com
Via Chartmill · February 25, 2026
This healthcare technology firm develops robotic surgical systems for minimally invasive urology procedures targeting BPH treatment.
Via The Motley Fool · February 1, 2026
The robotics infrastructure layer is delivering explosive returns.
Via The Motley Fool · October 29, 2025

Via Benzinga · February 26, 2025
Is Procept BioRobotics Stock a Buy After Investment Company Chicago Capital Scoops Up Nearly 1 Million Shares?
Via The Motley Fool · October 24, 2025
Via Benzinga · October 15, 2025
Via Benzinga · September 2, 2025
PROCEPT BioRobotics posted strong Q2 2025 revenue growth of 48% YoY but missed profitability estimates, triggering an 8% stock drop. The surgical robotics firm raised full-year guidance but faces investor concerns over rising costs and ongoing losses.
Via Chartmill · August 6, 2025
Via Benzinga · August 5, 2025

Spruce Point Capital warns of Procept BioRobotics' overstated market potential and growth claims, citing niche product limitations and valuation risks.
Via Benzinga · January 16, 2025

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Via Benzinga · December 2, 2024

